NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Price, News & Analysis

ProQR Therapeutics logo
$1.04 -0.01 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 -0.02 (-1.83%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About ProQR Therapeutics Stock (NASDAQ:PRQR)

Advanced

Key Stats

Today's Range
$1.00
▼
$1.07
50-Day Range
$1.05
▼
$1.90
52-Week Range
$1.00
▼
$2.49
Volume
920,559 shs
Average Volume
752,198 shs
Market Capitalization
$109.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60
Consensus Rating
Moderate Buy

Company Overview

ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery.

Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.

ProQR’s activities include drug discovery and development, and it has partnered with Eli Lilly on RNA-editing research. Its work is focused on research and clinical development rather than a portfolio of marketed medicines.

AI Generated. May Contain Errors.

ProQR Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

PRQR MarketRank™: 
3.65927143248 of 5 stars

ProQR Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 152nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    ProQR Therapeutics has a consensus price target of $7.60, representing about 648.8% upside from its current price of $1.02.

  • Amount of Analyst Coverage

    ProQR Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ProQR Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ProQR Therapeutics is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ProQR Therapeutics is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ProQR Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.99% of the float of ProQR Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    ProQR Therapeutics has a short interest ratio ("days to cover") of 2.93, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ProQR Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving.
  • Dividend Yield

    ProQR Therapeutics does not currently pay a dividend.

  • Dividend Growth

    ProQR Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    ProQR Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for ProQR Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for PRQR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    8.40% of the stock of ProQR Therapeutics is held by insiders.

  • Percentage Held by Institutions

    32.65% of the stock of ProQR Therapeutics is held by institutions.

  • Read more about ProQR Therapeutics' insider trading history.
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRQR Stock News Headlines

What is HC Wainwright's Estimate for PRQR FY2026 Earnings?
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
ProQR Therapeutics N.V. (PRQR)
See More Headlines

PRQR Stock Analysis - Frequently Asked Questions

ProQR Therapeutics' stock was trading at $2.02 on January 1st, 2026. Since then, PRQR shares have decreased by 49.8% and is now trading at $1.0150.

ProQR Therapeutics N.V. (NASDAQ:PRQR) issued its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The biopharmaceutical company earned $5.84 million during the quarter, compared to the consensus estimate of $4.30 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 72.78% and a negative net margin of 205.68%.

ProQR Therapeutics (PRQR) raised $90 million in an IPO on Thursday, September 18th 2014. The company issued 7,500,000 shares at $11.00-$13.00 per share.

Top institutional shareholders of ProQR Therapeutics include Privium Fund Management B.V. (5.19%), Marshall Wace LLP (1.06%), Aberdeen Group plc (0.11%) and Alpha Wealth Funds LLC (0.02%). Insiders that own company stock include Boer Daniel Anton De and Bart Filius.
View institutional ownership trends
.

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProQR Therapeutics investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Solid Biosciences (SLDB), Verastem (VSTM), NIO (NIO), ADMA Biologics (ADMA) and Aldeyra Therapeutics (ALDX).

Company Calendar

Last Earnings
11/12/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PRQR
CIK
1612940
Fax
N/A
Employees
166
Year Founded
2012

Price Target and Rating

High Price Target
$10.00
Low Price Target
$3.00
Potential Upside/Downside
+630.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.73 million
Net Margins
-205.68%
Pretax Margin
-210.96%
Return on Equity
-72.78%
Return on Assets
-36.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.21
Quick Ratio
3.21

Sales & Book Value

Annual Sales
$17.99 million
Price / Sales
6.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.74 per share
Price / Book
1.41

Miscellaneous

Outstanding Shares
105,360,000
Free Float
96,513,000
Market Cap
$109.57 million
Optionable
Optionable
Beta
0.29

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:PRQR) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners